Literature DB >> 15457928

Role of histamine and platelet-activating factor in allergic rhinitis.

V Alfaro1.   

Abstract

This review is focused on the effects of histamine and platelet-activating factor (PAF) in allergic rhinitis and the plausible implications for therapy. Rhinitis is defined as a heterogeneous disorder resulting from an IgE-mediated reaction associated with nasal inflammation of variable intensity. Two phases of response are triggered by an IgE/allergen cross-linking event: the first is the release of preformed mediators such as histamine or interleukins from mast cells and basophils; the second begins when cells start producing lipid-derived mediators. One of these mediators is PAF. Apart from leukotrienes, PAF is perhaps the most potent inflammatory mediator in allergic rhinitis for inducing vascular leakage, a response that may contribute to the appearance of rhinorrhea and nasal congestion.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15457928     DOI: 10.1007/BF03168446

Source DB:  PubMed          Journal:  J Physiol Biochem        ISSN: 1138-7548            Impact factor:   5.080


  93 in total

1.  Dual antagonists of platelet activating factor and histamine. Identification of structural requirements for dual activity of N-Acyl-4-(5,6-dihydro-11H-benzo [5,6]cyclohepta-[1,2-b]pyridin-11-ylidene)piperidines.

Authors:  J J Piwinski; J K Wong; M J Green; A K Ganguly; M M Billah; R E West; W Kreutner
Journal:  J Med Chem       Date:  1991-01       Impact factor: 7.446

2.  Study of the effects of paf-acether on human nasal airways.

Authors:  E Leggieri; A Tedeschi; M Lorini; A Bianco; A Miadonna
Journal:  Allergy       Date:  1991-08       Impact factor: 13.146

Review 3.  Histamine receptors: subclasses and specific ligands.

Authors:  E E Haaksma; R Leurs; H Timmerman
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

Review 4.  Functional and structural features of plasma platelet-activating factor acetylhydrolase.

Authors:  L W Tjoelker; C Eberhardt; C Wilder; G Dietsch; H L Trong; L S Cousens; G A Zimmerman; T M McIntyre; D M Stafforini; S M Prescott; P W Gray
Journal:  Adv Exp Med Biol       Date:  1996       Impact factor: 2.622

5.  High serum IgE concentrations: association with HLA-DR and markers on chromosome 5q31 and chromosome 11q13.

Authors:  M Ulbrecht; T Eisenhut; J Bönisch; R Kruse; M Wjst; J Heinrich; H E Wichmann; E H Weiss; E D Albert
Journal:  J Allergy Clin Immunol       Date:  1997-06       Impact factor: 10.793

6.  The effects of anti-PAF and other agents on the nasal symptoms in sensitized guinea pigs.

Authors:  S Narita; K Asakura
Journal:  Auris Nasus Larynx       Date:  1993       Impact factor: 1.863

7.  Evidence of PAF-acether metabolic pathway activation in antigen challenge of upper respiratory airways.

Authors:  A Miadonna; A Tedeschi; B Arnoux; A Sala; C Zanussi; J Benveniste
Journal:  Am Rev Respir Dis       Date:  1989-07

8.  The regulation of platelet-activating factor production in endothelial cells. The role of calcium and protein kinase C.

Authors:  R E Whatley; P Nelson; G A Zimmerman; D L Stevens; C J Parker; T M McIntyre; S M Prescott
Journal:  J Biol Chem       Date:  1989-04-15       Impact factor: 5.157

9.  Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators).

Authors:  C A Demopoulos; R N Pinckard; D J Hanahan
Journal:  J Biol Chem       Date:  1979-10-10       Impact factor: 5.157

10.  Mediator release during nasal provocation. A model to investigate the pathophysiology of rhinitis.

Authors:  A Togias; R M Naclerio; D Proud; C Baumgarten; S Peters; P S Creticos; J Warner; A Kagey-Sobotka; N F Adkinson; P S Norman
Journal:  Am J Med       Date:  1985-12-20       Impact factor: 4.965

View more
  8 in total

1.  Diode laser treatment in therapy-resistant allergic rhinitis: impact on nasal obstruction and associated symptoms.

Authors:  Philipp P Caffier; Hans Scherer; Konrad Neumann; Sven Lück; Harald Enzmann; Andreas Haisch
Journal:  Lasers Med Sci       Date:  2010-07-10       Impact factor: 3.161

2.  Therapeutic effects of intranasal tocotrienol-rich fraction on rhinitis symptoms in platelet-activating factor induced allergic rhinitis.

Authors:  Cheryl Wei Ling Teo; Stephanie Jia Ying Png; Yee Wei Ung; Wei Ney Yap
Journal:  Allergy Asthma Clin Immunol       Date:  2022-06-13       Impact factor: 3.373

3.  Atorvastatin prevents glomerular extracellular matrix formation by interfering with the PKC signaling pathway.

Authors:  Yan-Hua Xiao; Xiao-Yun He; Qing Han; Fan Yang; Su-Xian Zhou
Journal:  Mol Med Rep       Date:  2018-03-09       Impact factor: 2.952

Review 4.  Platelet-Activating Factor (PAF) in Allergic Rhinitis: Clinical and Therapeutic Implications.

Authors:  Rosa M Muñoz-Cano; Rocio Casas-Saucedo; Antonio Valero Santiago; Irina Bobolea; Paula Ribó; Joaquim Mullol
Journal:  J Clin Med       Date:  2019-08-29       Impact factor: 4.241

5.  Higher efficacy of rupatadine 20 mg and 10 mg versus placebo in patients with perennial allergic rhinitis: a pooled responder analysis.

Authors:  Antonio Valero; Iñaki Izquierdo; Marek L Kowalski; Glenis K Scadding; Jean Bousquet; Joaquim Mullol
Journal:  Allergy Asthma Clin Immunol       Date:  2020-04-23       Impact factor: 3.406

6.  A direct comparison of efficacy between desloratadine and rupatadine in seasonal allergic rhinoconjunctivitis: a randomized, double-blind, placebo-controlled study.

Authors:  Kf Lukat; P Rivas; A Roger; Ml Kowalski; U Botzen; F Wessel; F Sanquer; I Agache; I Izquierdo
Journal:  J Asthma Allergy       Date:  2013-02-22

Review 7.  Inflammation, not Cholesterol, Is a Cause of Chronic Disease.

Authors:  Alexandros Tsoupras; Ronan Lordan; Ioannis Zabetakis
Journal:  Nutrients       Date:  2018-05-12       Impact factor: 5.717

8.  Clinically relevant effect of rupatadine 20 mg and 10 mg in seasonal allergic rhinitis: a pooled responder analysis.

Authors:  Joaquim Mullol; Iñaki Izquierdo; Kimihiro Okubo; Giorgio Walter Canonica; Jean Bousquet; Antonio Valero
Journal:  Clin Transl Allergy       Date:  2019-10-09       Impact factor: 5.871

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.